Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200MeV

Weidner, John W.; Mashnik, S. G.; John, Kevin D.; Hemez, François M.; Ballard, B.; Bach, H.; Birnbaum, Eva R.; Bitteker, Leo; Couture, A.; Dry, D. E.; Fassbender, Michael E.; Gulley, M. S.; Jackman, Kevin; Ullmann, J. L.; Wolfsberg, Laura E.; Nortier, F.M.

doi:10.1016/j.apradiso.2012.07.006

Cited by 73 publications

(82 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27]. The spallation of 232 Th to produce 225 Ac, however, has been receiving enhanced attention and some detailed measurements have been reported [28,29]. Further work on the formation of impurities is continuing [cf.…”

Section: Novel Therapeutic Radionuclidesmentioning

confidence: 99%

Nuclear data for medical applications: An overview of present status and future needs

Syed

2017

EPJ Web Conf.

View full text Add to dashboard Cite

Abstract.A brief overview of nuclear data required for medical applications is given. The major emphasis is on radionuclides for internal applications, both for diagnosis and therapy. The status of the presently available data is discussed and some of the emerging needs are outlined. Most of the needs are associated with the development of non-standard positron emitters and novel therapeutic radionuclides. Some new developments in application of radionuclides, e.g. theranostic approach, multimode imaging, radionanoparticles, etc. are described and the related nuclear data needs are discussed. The possible use of newer irradiation technologies for medical radionuclide production, e.g. intermediate energy charged-particle accelerators, high-power electron accelerators for photon production, and spallation neutron sources, will place heavy demands on nuclear data.

show abstract

Section: Novel Therapeutic Radionuclidesmentioning

confidence: 99%

Nuclear data for medical applications: An overview of present status and future needs

Syed

2017

EPJ Web Conf.

View full text Add to dashboard Cite

show abstract

“…Thats why they can easily induce the medically required double-strand DNA break in the tumor cells without damaging the 99 Mo production by charged particle activation on natural Mo [6,7,18,19] and 100 Mo enriched targets [20] surrounding healthy cells. New results have been published for the α-particle and proton induced production of 211 At [22] and 225 Ac [23,24] respectively. The actinide radioisotope 225 Ac has a half-life of 10 days, emits four alpha particles in its decay chain, and has recently gained importance for application in future treatment of metastatic cancer via targeted α-immunotherapy [25].…”

Section: Heavy α-Emittersmentioning

confidence: 99%

New developments in the experimental data for charged particle production of medical radioisotopes

Ditrói

Tárkányi

Takács

et al. 2015

J Radioanal Nucl Chem

View full text Add to dashboard Cite

The goal of the present work is to give a review of developments achieved experimentally in the field of nuclear data for medically important radioisotopes in the last three years. The availability and precision of production related nuclear data is continuously improved mainly experimentally. This review emphasizes a couple of larger fields: the Mo/Tc generator problem and the generator isotopes in general, heavy alpha-emitters and the rare-earth elements. Other results in the field of medical radioisotope production are also listed.

show abstract

“…82]. A third possibility under investigation is its production via irradiation of 232 Th with intermediate energy protons [83][84][85]. The yield of 225 Ac and the level of the 227 Ac (T 1/2 = 21.8 a) impurity calculated from the recently reported data [83] are given in Fig.…”

Section: Novel Therapeutic Radionuclidesmentioning

confidence: 99%

New trends in nuclear data research for medical radionuclide production

Qaim

2013

Radiochimca Acta

View full text Add to dashboard Cite

Medical radionuclide / Optimisation of production route / Nuclear reaction cross section / Standardisation of data / Alternative routes for production of 99m Tc and 68 Ga / Non-standard positron emitter / Novel therapeutic radionuclide Summary. Nuclear reaction cross section data are of great significance in optimisation of production routes of radionuclides. This article deals with some newer aspects of data research related to production of both standard and novel radionuclides. The recent work to standardise the known data is discussed and new measurements with regard to further optimisation of production routes of some commonly used radionuclides are mentioned. Attempts to increase the specific activity of some reactor-produced radionuclides through the use of charged-particle induced reactions are outlined. The jeopardy in the supply of 99m Tc via a fission-produced 99 Mo/ 99m Tc generator is considered and its possible direct production at a cyclotron is briefly discussed. Regarding the novel radionuclides, development work is presently focussed on non-standard positron emitters for diagnosis and on low-range highly ionising radiation emitters for internal radiotherapy. Recent nuclear reaction cross section measurements related to the production of the two types of radionuclides are briefly reviewed and some anticipated trends in nuclear data research are considered.

show abstract

Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200MeV

Cited by 73 publications

References 17 publications

Nuclear data for medical applications: An overview of present status and future needs

Nuclear data for medical applications: An overview of present status and future needs

New developments in the experimental data for charged particle production of medical radioisotopes

New trends in nuclear data research for medical radionuclide production

Contact Info

Product

Resources

About